The report includes historical data from 2023 to 2024 and forecasts until 2033. The insulin pen market in the United States has experienced remarkable growth over the last few years.

The insulin pens market is witnessing significant growth due to the increasing prevalence of diabetes worldwide and the rising preference for advanced, user-friendly insulin delivery systems. Insulin ...

The global Smart Insulin Pens Market is experiencing substantial growth, driven by the increasing prevalence of diabetes, advancements in digital healthcare solutions, and the demand for user-friendly ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities. | Citing "capacity constraints ...

A doctor and honorary researcher at the University of Exeter is leading a campaign to make reusable insulin pens the standard for treating diabetes patients. Dr Vincent Simpson aims to cut down on ...

As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will leave them in the lurch.